Lung Cancer: Novel Therapeutic Approaches

Dear Colleagues,

In addition to the conventional three major treatment methods of surgery, chemotherapy, and radiation therapy, the effectiveness of immunotherapy has recently been proven, and it has become one of the four major treatment methods for lung cancer. In particular, various molecular targeted drugs and angiogenesis inhibitors have been developed for chemotherapy, and in immunotherapy, not only immune checkpoint inhibitors but also cancer vaccine therapies have been developed and many clinical trials are being conducted. At the same time, many biomarkers have been discovered, and personalized treatment for each patient is beginning to prevail worldwide.

Now, in addition to these four major existing treatments, we must also pay attention to the fifth treatment. For example, photodynamic therapy and photothermal therapy have been reported to be effective in the local treatment of cancer and are attracting attention. I believe that there are other treatment methods derived from translational research that are still at the animal experiment level. In addition, new technologies may make it possible to diagnose lesions less invasively or with a higher positive diagnosis rate, leading to treatment without rate-limiting steps.

This theme invites original papers, case reports, and clinical trials, in addition to reviews of new therapies, including combinations of existing therapies. We are also looking for new diagnostic modalities directly related to treatment. In addition to the treatment of primary lung cancer, treatment methods related to tumors that occur in the chest, such as metastatic lung tumors and mediastinal tumors, are also welcome. We hope that this will lead to higher therapeutic efficacy in the treatment of lung cancer in the future.

Potential topics include, but are not limited to:

• New surgical methods (including resection methods, approaches, and anesthesia)
• New drug therapies (including chemotherapy, gene therapy, and immunotherapy)
• New cell therapies (including immune cell therapy)
• Phototherapy
• Other new treatment methods
• Combination of existing treatments

Dr. Tomonari Kinoshita
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• lung neoplasm
• new therapy
• combined therapy